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Corticosteroids are the most effective way 
to treat ocular inflammation. They relieve 
symptoms rapidly and often prevent 
permanent damage. These medications, 
however, must be used with caution, as use 
of steroid-containing topical drops can lead 
to serious side-effects. In situations where 
resources are limited it is often difficult to 
decide if steroids can be given safely. The 
purpose of this article is to briefly review the 
most important features of topical steroids 
and provide a practical and safe guideline 
for their use in general practice (Fig. 1 and 
Table 1).  
Mechanism of action 
Topical steroids act locally and achieve 
their anti-inflammatory and immuno-
suppressive effects through a combination 
of pathways. The most important anti-
inflammatory effect may be the inhibition 
of arachidonic acid release, preventing the 
liberation of prostaglandins and other potent 
inflammatory mediators. The immuno-
suppressive effects include decreasing the 
number and functionality of leucocytes. 
Steroids also prevent late inflammatory 
responses, such as capillary and fibroblast 
proliferation, collagen deposition and 
scarring.
Common indications 
Severe allergic keratoconjunctivitis (the 
main indication in general practice), 
adenoviral keratoconjunctivitis, uveitis, 
episcleritis, scleritis, corneal graft rejection, 
immunogenic keratitis and uveitis.[1,2] 
Side-effects 
Well-known complications of topical 
steroids include the formation of a 
geographic ulcer if given in the presence of a 
dendritic herpetic ulcer, cataract formation 
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Fig. 1. Guide to prescribing topical steroids in ophthalmic disorders.
Well-known 
complications of 
topical steroids include 
the formation of a 
geographic ulcer if 
given in the presence 
of a dendritic herpetic 
ulcer, cataract 
formation and 
increased intra-ocular 
pressure.
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and increased intra-ocular pressure (IOP). The increase in IOP can 
occur after only 1 week of treatment – 30% of the population will 
develop a moderate rise, while 4 - 5% will have a marked increase 
in IOP. This response can occur during any stage of treatment, and 
is more pronunced in children if the patient already has glaucoma, 
diabetes or high myopia. Regular IOP monitoring is needed to 
prevent damage to the optic nerve.[1,3,4]     
Topical steroids increase the risk of corneal infections due to 
suppression of the host’s response. This may lead to new infections, 
exacerbate existing infections, reactivate dormant infections and 
mask less obvious chronic infections, leading to delayed presentation 
of potentially blinding conditions.[1] Common conditions 
potentiated by steroid therapy without appropriate cover include 
viral (herpetic), bacterial (notably Pseudomonas aeruginosa, which 
is often contact-lens associated) and fungal keratitis. Other adverse 
effects include delayed wound healing, mydriasis, aponeurotic 
ptosis and peri-ocular dermatitis. In the presence of an underlying 
connective tissue disease which predisposes to corneal or scleral 
thinning, ocular perforation may occur.[1,4-6]  
Potency 
Most side-effects of topical steroids are related to the specific 
corticosteroid’s potency, duration of action and ability to penetrate 
the globe. Formulations with acetates are more lipophilic and 
penetrate through the cornea better than those formulated with 
phosphates, which are relatively hydrophilic.[6] If hydrocortisone has 
a relative effect of a factor 1, then betamethasone, dexamethasone 
and tri- amcinolone respectively have a 25, 30 and 35 times more 
potent anti-inflammatory effect.[6]
Prescribing 
Topical steroids should only be prescribed if the benefit outweighs 
the risks. In severe allergic keratoconjunctivitis, fluoromethalone 
alcohol suspension (0.1 - 0.25%) can be used with relative impunity. 
Table 1. Topical steroid formulations available in South Africa[3,6,7] 
Drugs in order of 
increasing potency Trade name
Steroid half-
life (hrs)
Potency 
compared with 
hydrocortisone Side-effect Indications
Single preparations
Prednisolone acetate 0.12% Pred-Mild 18 - 36 4 Worsening 
of external 
infection
Allergic 
keratoconjunctivitis,
inflamed pterygium,
inflammatory causes of 
dry eyes,
episcleritis
Fluoromethalone 0.1% FML Liquifilm
Flucon
NA  21
Betamethasone 0.1% Betnesol 36 - 54 25
Dexamethasone phosphate 0.1% Maxidex
Spersadex
36 - 54 30 Cataracts,
IOP elevation, 
corneo-scleral 
thinning and 
perforation
Uveitis, corneal graft 
rejection,
immunogenic keratitis, 
scleritis
Prednisolone acetate 1% Pred Forte 18 - 36 40
Combined preparations
Betamethasone, neomycin Betnesol N 36 - 54
Dexamethasone, 
chloramphenicol
Covomycin D 36 - 54
Fluoromethalone, neomycin FML-Neo
Dexamethasone, neomycin, 
polymyxin B
Maxitrol 36 -54 Masks hyper-
sensitivity
Bacterial 
resistance
Postoperative 
prophylaxis,
e.g. post cataract 
surgery
Dexamethasone, framycetin, 
gramicidin
Sofradex 36 - 54
Dexamethasone, 
chloramphenicol
Spersadex Comp 36 - 54
Hydrocortisone, oxytetracycline, 
polymixin B
Terra-Cortril 8 - 12
Dexamethasone, tobramycin Tobradex 36 - 54
Topical steroids should only be 
prescribed if the benefit outweighs 
the risks.
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It has a potent anti-inflammatory effect on 
the ocular surface, but rapid metabolism 
of the compound within the eye decreases 
the intra-ocular potency and intra-
ocular side-effects.[1] It has been found to 
be almost as effective in ocular surface 
inflammatory conditions as dexamethasone 
or prednisolone acetate 0.125%, while 
having the distinct advantage of a lower 
incidence of steroid-induced glaucoma. 
The risk of corneal ulcers, however, remains 
unchanged.[7] Medrysone 1% may also be 
used in ocular surface inflammation. It 
penetrates the globe poorly and is even less 
likely to cause steroid glaucoma.[5] 
Dexamethasone 0.1% is considered a potent 
steroid. It penetrates the cornea more readily 
and has a long half-life in ocular tissues. It is 
therefore more suitable for reaching deeper 
ocular tissues (as is needed in uveitis), but 
has a higher risk of significant IOP elevation 
and cataract formation compared with 
fluoromethalone 0.1%.[1,6] Dexamethasone is 
often contained in combination antibiotic/
steroid preparations. These combinations 
are indicated for use in the postoperative 
period (i.e. after cataract surgery), and are 
not registered for empirical use in blepharitis 
or conjunctivitis of unknown cause.[7]
Acute adenoviral follicular conjunctivitis 
(‘pink eye’) is very common in primary 
practice. Most clinicians would withhold 
topical steroids except in severe cases provided 
there is no evidence of corneal involvement. 
Recent evidence now supports the use of 
topical dexamethasone 0.1% 4 times a day 
for 1 week in acute follicular conjunctivitis 
presumed to be viral in origin.[9]
Prednisolone acetate 1% suspension 
(i.e. Pred Forte) exhibits the greatest 
anti-inflammatory activity of all the 
corticosteroids on the anterior segment 
of the eye.[1,5] It therefore has a high risk of 
steroid-related complications (Table 1).  
Loteprednol etabonate and rimexolone 
are new-generation synthetic steroids, 
specifically designed to minimise some of 
the adverse effects of topical steroids. IOP 
elevation has been reported but is rare, even 
in known steroid responders. Current data 
also suggest decreased potential for cataract 
formation.[1,2] These drugs are currently 
marketed for temporary use in allergic 
keratoconjuntivitis.
Conclusion 
Family practitioners may safely prescribe 
topical steroids, provided they have 
acquired the skill to assess and monitor the 
side-effects of topical steroids (Fig. 1). 
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In situations where 
resources are limited 
it is often difficult to 
decide if steroids can 
be given safely.
In a nutshell
• Before prescribing topical steroids:
• Take an adequate clinical history.
• Exclude the following three high-risk situations:
• Glaucoma – by measuring the intra-ocular pressure with a Schiotz or other tonometer; 
minimally assess the IOP digitally
• Cataract – by performing a red reflex test
• Herpes simplex or fungal keratitis – by staining the corneal surface with fluorescein 
and examining it with a cobalt blue light using the +10 magnification (now standard on 
direct ophthalmoscopes)
• Monitor the IOP if treatment exceeds 2 weeks.
• Ideally have access to a slit-lamp.
• Follow the guidelines to prescribing topical steroids in ophthalmic disorders.
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